Gene therapy for renal cancer

Y. Haviv, D. Curiel

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

2 Scopus citations


Recent advances in understanding the molecular events associated with renal cell carcinoma (RCC) are revolutionizing the therapeutic options offered for patients with advancedstage RCC. These targeted approaches for RCC are based primarily on antiangiogenesis and/or specific kinase inhibitors targeting the vascular-endothelial growth factor and platelet-derived growth factor receptors, Raf and mammalian target of rapamycin inhibitor. In this context, characterization of the molecular events unique to RCC is also of critical significance for gene therapy endeavors. The attributes of gene therapy for RCC may include true targeting to cancer cells, transfer of immunomodulatory or antiangiogenic genes and novel nonapoptotic cancer cell killing mechanisms. Gene therapy may thus become a promising new adjuvant modality for RCC and expand the therapeutic armamentarium against RCC. Beyond the current stage of preclinical proof of principle and toxicological analysis in animal models, the utility of RCC gene therapy will depend on safety and efficacy trials in human subjects. These trials will determine whether targeted therapy for RCC employing genome-based strategies will broaden the current therapeutic spectrum for RCC comprising kinome-based, immunomodulatory and antiangiogenesis strategies.

Original languageEnglish
Title of host publicationGene Therapy for Renal Diseases and Transplantation
EditorsAriela Benigni, Remuzzi Giuseppe
Number of pages16
StatePublished - 20 Aug 2008
Externally publishedYes

Publication series

NameContributions to Nephrology
ISSN (Print)0302-5144

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Gene therapy for renal cancer'. Together they form a unique fingerprint.

Cite this